|
Trial no.:
|
PACTR202009710020465 |
Date of Registration:
|
01/09/2020 |
|
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
| TRIAL DESCRIPTION |
|
Public title
|
'PrEP in Pharmacy - Pilot study |
| Official scientific title |
Pharmacy delivery to expand the reach of PrEP in Kenya: Pilot study |
|
Brief summary describing the background
and objectives of the trial
|
Maximizing access, minimizing costs of delivery, and reaching at-risk populations are key priorities for 173 optimizing the public health impact of pre-exposure prophylaxis (PrEP) for HIV prevention. In Africa, PrEP 174 is being added to an already-burdened public health infrastructure and the ability of the health systems 175 to maximize PrEP access will necessitate finding novel delivery strategies. In feasibility evaluations of 176 PrEP in Africa to date, major barriers to PrEP delivery include stigma, long waiting times, the costs of 177 staffing, and healthcare providers’ unfamiliarity with delivering prevention interventions.
In Kenya, retail pharmacies fill an important gap in the health care system, providing access to treatment 179 of urgent conditions (e.g., evaluation and medication for STIs, upon presentation of a valid prescription), 180 monitoring of chronic conditions (e.g., blood pressure testing), and preventative care (e.g., 181 contraception). HIV testing is also now legally allowed at pharmacies through purchase of HIV self-tests 182 or pharmacy provider-assisted HIV self-testing. Pharmacy-delivered care has many attributes that may 183 be desirable for potential PrEP users, including convenience (as pharmacies outnumber clinics and have 184 shorter waiting times), anonymity (compared to seeking PrEP at an HIV care center), and engagement 185 (which may be greater for a preventative service at a pharmacy than at a clinic that prioritizes treating ill 186 individuals). Pharmacies can offer free, subsidized, or fully fee-for-service care, and paying for a service 187 could result in greater sustained consumer engagement. |
| Type of trial |
CCT |
| Acronym (If the trial has an acronym then please provide) |
|
| Disease(s) or condition(s) being studied |
Infections and Infestations |
| Sub-Disease(s) or condition(s) being studied |
HIV/AIDS |
| Purpose of the trial |
Prevention |
| Anticipated trial start date |
31/08/2020 |
| Actual trial start date |
|
| Anticipated date of last follow up |
30/06/2021 |
| Actual Last follow-up date |
|
| Anticipated target sample size (number of participants) |
300 |
| Actual target sample size (number of participants) |
|
| Recruitment status |
Not yet recruiting |
| Publication URL |
|
|